drugset / Trial / NCT02052024

Myobloc Atrophy Study

NCT02052024

RandomizedParallel-groupOpen-labelTreatment

Summary

The present pilot study is designed to assess the extent to which BOTOX and MYOBLOC cause muscle atrophy in spastic patients. The primary objective is to assess whether there is statistically significant difference in muscle atrophy between the two groups over a one year period.

Timeline

Start
2014-05
Primary completion
2015-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum Toxin Type B Unknown 5000 iu
Comparator Botulinum toxin type A Protein / enzyme biologic 100 iu